Strains of Escherichia coli carrying R-factor R71(a), which codes for a streptomycin-spectinomycin adenylyltransferase, have elevated levels of resistance to dihydrostreptomycin (DHS) compared with isogenic R-bacteria. DHS accumulated by whole cells and spheroplasts of R+ bacteria is lower than that observed for R-strains, a result of the absence of the second and more rapid of the two energy-dependent phases of DHS uptake seen in susceptible E. coli. A mutant of R+ E. coli with reduced DHS resistance has been shown to have reduced levels of streptomycin-spectinomycin adenylyltransferase activity as well as enhanced drug accumulation. Actively accumulated DHS was recovered from R+ cells as the adenylylated derivative. Neither was inactivated antibiotic detected in culture filtrates, nor was actively accumulated drug lost from R+ cells under normal conditions. The cellular distribution of actively accumulated DHS in R+ and Rcells was found to be the same. Membranes isolated from these cells retained only a small fraction (=1%) of the total cell-associated drug. The R+ derivative of a mutant with defective energy transduction (E. coli NR-70) and reduced ability to transport aminoglycosides has a significantly higher minimal inhibitory concentration of DHS than its R+ parent (strain 7). Streptomycin-spectinomycin adenylyltransferase activity, from comparisons of Km values and total activities of enzyme, was the same in both strains. The enzyme has been localized to the exterior surface of the bacterial inner membrane, although isolated membranes lacked detectable enzyme activity. The preceding observations are consistent with the proposal that the level of R71(a)-mediated DHS resistance is the outcome of competition between the rate of adenylylation and the rate of the first energy-dependent phase of DHS transport. When the rate of adenylylation exceeds the first energy-dependent phase, adenylylated DHS is accumulated, apparently in a manner identical to the accumulation of DHS. Unlike DHS, adenylylated DHS does not interact with ribosomes, and, consequently, there is a failure to initiate ribosomally dependent sequelae such as the second energydependent phase of accumulation, inhibition of protein synthesis, and/or misreading of mRNA. R-factor-specified enzymatic modification of aminoglycoside antibiotics has been shown repeatedly to be a clinically important mechanism of resistance to aminoglycosides in bacteria. However, the precise mechanism by which enzymatic modification causes resistance is unknown. It has been shown in certain instances that modified aminoglycosides are no longer as effective at inhibiting protein synthesis or producing misreading of mRNA (23). These observations fail to explain aminoglycoside resistance because it has been demonstrated that only a very small fraction (less than 1%) of the total available, active aminoglycoside in the bacterial growth medium is detoxified. Thus, bacteria possessing aminoglycoside-inactivating enzymes are able to multiply in a milieu of almost entirely active drug. Another observation reported is that R+ bacteria which possess inactivating enzymes accumulate less aminoglycoside antibiotic than do isogenic R-bacteria (L. E. Bryan and H. M. Van Den Elzen, Progr. Abstr. Intersci.
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The study undertaken employed as a model system E. coli strains clinically resistant to dihydrostreptomycin (DHS) due to the presence of an R-factor with the genetic determinants for a streptomycin-spectinomycin adenylyltransferase [AAD-(3")].
MATERIALS AND METHODS Bacterial strains and selective techniques. E. coli K-12 J5 F-pro met azider (5) was the source of R-factor R71(a). Recipients for R71(a) were rifampin resistant derivatives (Rifr; selected for resistance to 100 ,ug of rifampin per ml) of E. coli K-12 SA1306 (4), E. coli ML308.225 lacA lacZ obtained from M. Pickard (University of Alberta, Edmonton, Alberta), E. coli K-12 strain 7 Cavalli Hfr (18) , and E. coli K-12 NR-70 ATPase-Unc-, a mutant derivative of strain 7 derived by B. Rosen (18) 20 ,ug/ml, and the suspension was incubated for 30 min at 37°C.
Reactions were terminated in the former case by washing spheroplasts with the phosphate buffer and sucrose and in the latter case by chilling plus the addition of 50 ,ug of soybean inhibitor per ml (1 mg inhibited 1.5 mg of trypsin or 10,000 BAEE U/mg). Preparations were sonically disrupted in 0.025 M sodium phosphate buffer, pH 8. Controls included untreated samples, treated sonic extracts, sonic extracts plus soybean inhibitor (50 ug/ml), and sonic extracts treated with preformed inhibitor-trypsin complex to identical final concentrations (five parts inhibitor to two parts enzyme mixed on ice for 15 min).
Other methods. Protein was measured by a modified Lowry method (8 Modollel (15) . The assay for ribosomal binding of DHS has been described by Chang and Flaks (6 Determination of antibiotic susceptibilities of bacterial strains. Minimum inhibitory concentrations (MICs) for DHS and spectinomycin and disk susceptibilities were performed as described previously (4), with the exception that MICs were determined in nutrient broth.
RESULTS
DHS sensitivity and accumulation in Rs and R-whole cells and spheroplasts. The presence of R-factor R71(a) in recipient E. coli strains resulted in a several-fold increase of MIC of DHS (Table 1) . Streptomycin adenylyltransferase activity was detectable in cell-free extracts of the R+ organisms, whereas recipient bacteria had no such activity. R+ bacteria also acquired resistance to tetracycline, chloramphenicol, sulfonamides, and ampicillin as determined by disk sensitivity tests. The DHS resistance produced by R71(a) was much lower than that due to a strA ribosomal mutation. As shown in Table 1 , ribosomes from R+ and R-bacteria bound DHS, whereas those from strA cells did not.
Mutants of R+ bacteria with reduced MICs of DHS and spectinomycin have a corresponding decrease in adenylyltransferase activity compared with the R-parent (Table 1) . A similar relationship has previously been described by Benveniste et al. (1) . These mutants were isolated after methanesulfonic acid ethyl ester mutagenesis by selecting clones with impaired growth on medium selective for R+ strains containing 15 ,ug of DHS per ml. Mutants retained normal levels of resistance to the other four antibiotics, and the reduced MICs of DHS and spectinomycin were stable properties. The mutation is most likely a single-point mutation because reversion to usual MICs for both drugs occurred in about 1 in 105 clones. Also, methanesulfonic ethyl ester mutagenesis has a high probability of producing point transitions (16) . Mutant SR15 was selected to study the significance of adenylylating activity on DHS transport.
The kinetic profile for DHS accumulation by VOL. 14, 1978 susceptible E. coli is represented in Fig. 1 . Uptake occurs in three stages. These have been described in detail elsewhere (4) and are designated, in the order of their occurrence, the energy-independent phase, the first energy-dependent phase (EDP-I), and the second energydependent phase (EDP-II). The energy dependence of the latter two phases is apparent from their absence in cells treated with the electron transport inhibitor potassium cyanide. The energy-independent phase, essentially complete before the taking of the first reading, is the only phase present in KCN-treated cells (R+ or R-).
R+ cells differ from R-cells in accumulating less drug at the same drug concentrations after 30-min incubation periods ( Fig. 1 and 2a) DHS accumulation by spheroplasts of R+ and R-E. coli is similar to that seen with whole cells (Fig. 2) . The difference in total uptake between spheroplasts of R-and R+ bacteria is also attributable to the absence of EDP-II in R+ sphero- phosphatase is readily lost to the suspending fluid, adenylyltransferase is retained by spheroplasts (Table 3) . This is consistent with the reduced DHS accumulation observed in spheroplasts of R+ cells.
The preceding results suggest that the AAD-(3") is associated with the bacterial cell membrane. A crude membrane fraction of osmotically shocked cells was prepared and assayed for residual enzyme activity. As shown in Table 2 , no more than contaminating levels of enzyme were detected. Membrane vesicles prepared as described by Kaback (10) from ML308-225 R71(a) and suspended to 2.3 mg of protein per ml also had no activity when compared with membranes from R-bacteria. Solubilizing buffer had no significant effect on measured levels of enzyme activity in cell-free extract controls.
To assess the localization ofAAD-(3") further, reagents capable of enzymatic inactivation but unable to penetrate the intact cytoplasmic membrane were used to determine the degree to which the enzyme was inactivated in intact spheroplasts. The proteolytic enzyme trypsin and the reagent dye SITS were used. SITS reacts with amino, histidyl, and guanidyl groups of peptides (12) .
According to the results presented in Under these conditions DHS accumulation is by EDP-I kinetics only. These cells were washed, sonically disrupted, and centrifuged (see above). Supernatant fluids of sonically disrupted samples were chromatographed. R-cells were included as a control. As shown in Fig. 4 , after 15 min about one-quarter of the drug accumulated is adenylylated. After 30 min there is a greater increase in modified drug so that it represents about 40% of the total. These values correlate well with the fraction of cell-associated drug accumulated energetically after 15 and 30 min. The proportion of DHS represented by unmodified DHS is likely drug accumulated during the energy-independent phase. This is probable because the amount of drug accumulated per unit mass of cells by the energy-independent process is stable with time (see Fig. 1 ), whereas there is continuing accumulation by an energy-dependent process. Thus, the increasing fraction represents drug accumulated by the energy-dependent process. The absence of detectable adenylylated DHS in the growth medium also supports the concept that modified drug represents most if not all of the actively, irreversibly accumulated fraction of the cell-associated drug. Table 5 shows that the vast majority of the label has been released into the supernatant fluid chromatographed, indicating that the ratio expressed above is representative of the population of cellassociated drug as a whole.
The results of the previous experiment indicated that modified drug does not have high affinity for the bacterial cell membrane. To attempt to clarify this, membranes isolated from ML308.225 R71(a) having actively accumulated
[3H]DHS (at 0.5 ,ug/ml for 30 min) during EDP-I only were assayed for radioactivity. Little drug was retained by membrane fractions obtained after the fractionation of cells as described above. All but 1% of the cell-associated drug could be traced to the supernatant fluid. The distribution in R-cells was identical.
We are currently developing methods to improve the resolution of autoradiography so that whole-cell distribution of [3H]DHS can be accurately determined. Results from our observations to this time will be briefly described. E. coli K-12 SA1306 (R+ and R-) were incubated in NB with 1 Effect of transport mutations on DHS sensitivity in R+ bacteria. It has been shown that NR-70, an Unc-ATPase-mutant of E. coli strain 7, has a reduced capability to transport aminoglycosides (4) probably due to an impaired protonmotive force (19) . In turn, NR-70 has reduced susceptibility to various aminoglycosides including streptomycin when compared with strain 7. The effect of this reduced capability to transport [3H]DHS by NR-70 on R+-mediated DHS resistance was determined. R71(a) was introduced into NR-70 and strain 7, and MICs were determined. As shown in Table 6 , the MIC of DHS for R+ NR-70 was several times higher than for R+ strain 7. To confirm that the AAD-(3") activity was unchanged in strain NR-70, Km values determined from Lineweaver and Burk plots and total activity of the enzyme from NR-70 and strain 7 were compared. The results in Table 6 demonstrate that enzyme activity was identical and that the differential resistance of the two strains was due to the differences in DHS transport between NR-70 and strain 7 previously demonstrated (4) . DISCUSSION Resistance achieved by inactivation of less than 1% of the total amount of DHS or other aminoglycosides present in the growth medium by R-factor-specified aminoglycoside-modifying enzymes suggests that these enzymes interfere with drug transport. DHS accumulation has been shown in this study to be significantly reduced in R+ cells compared to R-cells. This reduction could be due to blocking further accumulation, to increased efflux, or to a change in influx kinetics independent of blocked trans- VOL. 14, 1978 . I
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The energetics and mechanics of aminoglycoside transport in susceptible bacteria have been studied and reported elsewhere (4). Accumulated evidence indicates that EDP-I represents the transport of drug across the cytoplasmic membrane to accessible ribosomal binding sites. Binding of drug by the ribosomes then initiates subsequent events such as enhanced transport (EDP-II), inhibition of protein synthesis, and the eventual onset of loss of cell viability. Recently, the enhanced transport has been proposed to be due to a polyamine transport system (9) . All these events are absent in strA bacteria whose ribosomes fail to bind streptomycin. Our results confirm the absence of EDP-II in R+ bacteria and the relationship of this effect and AAD-(3") activity. Nonetheless, R+ bacteria accumulate more drug during EDP-I than the amount required to initiate EDP-II in susceptible bacteria. Chromatographic analysis of cellassociated drug indicates that the proportion of DHS actively accumulated by R+ bacteria is in the adenylylated form. If the only DHS transported and presented to ribosomes was adenylylated, this alone would explain DHS resistance because adenylylated DHS does not bind to ribosomes (23) . It would also explain the reduction in DHS accumulation, because in the or enhanced aminoglycoside accumulation rates also support our conclusion of resistance being the outcome of competition between rates of inactivation and transport. We have, for example, examined various R-factors in mutants of P. aeruginosa PAO which initiate transport of aminoglycosides at reduced aminoglycoside concentrations and show faster transport at equivalent concentrations (compared with the parent). Resistance levels found with the R-factors in the mutants are 1/4 to 1/10 that seen with the Rfactor in the parent.
Only that fraction of DHS transported during EDP-I need be inactivated to ensure resistance. EDP-I declines in rate after 30 to 60 min, and no further uptake occurs after 60 to 120 min (4). An equilibrium is eventually established apparently due to saturation of available transport and binding sites at any given drug concentration. Such an equilibrium is usually reached when between 0.5 and 1% of the total drug present has been accumulated. Thus, only 0.5 to 1% of all drug need be inactivated, and complete detoxification of the medium is not required to achieve resistance. Small amounts of detoxified drug can be detected after a 30-min exposure of whole cells to DHS (see Fig. 4 ). This fraction represents <0.5% of the total DHS in the medium and corresponds closely to the amount actively accumulated during EDP-I after 30 min.
A physical as well as a functional association of AAD-(3") and the aminoglycoside transport system may exist. Davies and Benveniste have localized aminoglyside-inactivating enzymes in general to the cytoplasmic membrane. Our results are in agreement, at least for AAD-(3") in E. coli, and suggest further that the association is with the outer surface of this membrane. Retention of AAD-(3") activity by spheroplasts is not likely the result of the localization of enzyme with contaminating elements of cell wall material. The fact that the enzyme remains functionally active in spheroplasts supports the belief that it occupies an in situ position. Its partial accessibility to impermeable chemical reagents in spheroplasts demonstrates that it is external to the membrane permeability barrier and indicates an association with the outer membrane surface in whole cells. However, the enzyme can only be tenuously bound because isolated membrane vesicles are without activity. Its activity is not lipid dependent, and it is releasable during osmotic shocking, thus indicating a distinction from periplasmic and intrinsic membrane proteins.
It is now possible to propose a sequence of events occurring in R+ cells growing in the presence of DHS. As in susceptible cells, drug is probably immediately bound electrostatically to anionic components of the cell wall and then to sites deeper in the cell envelope, including the cell membrane. Energy is then required for the active and irreversible accumulation of drug bound to these inner membrane sites. Inactivation of the antibiotic must follow the first step in the process of irreversible binding because modified drug is not found in detectable quantities in the environment. This first step probably involves the electrostatic binding of drug to membrane sites (probably polar heads of phospholipids) and as such is available for transport. When electron transport is functional, the drug is transported across the membrane at a rate exceeding its dissociation from these sites. If electron transport is inhibited by the addition of KCN, then this population of drug is slowly lost from the cells (see Fig. 3 ). As inactivation rates exceed the rate of transport during EDP-I, only inactivated drug is presented to the ribosome at the inner surface of the membrane. Failing to bind to ribosomes, the drug accumulates until available cellular sites are saturated: an equilibrium is reached between the external cell concentration and cell binding sites. Net transport and inactivation would then cease.
Our observations suggest that transport of aminoglycosides occurs normally in R+ bacteria VOL. 14, 1978 and there is a failure to distinguish between modified and unmodified drug. Consistent with this, it has been shown that bacteria that modify gentamicin but not streptomycin when exposed to the two antibiotics simultaneously remain susceptible to streptomycin. Streptomycin transport is presumably not affected by the resistance mechanism active against gentamicin. The reverse situation also occurs in that R-factors modifying streptomycin like R71(a) do not affect susceptibility to gentamicin or other aminoglycosides. One important consideration from a clinical standpoint can be made at the present time. With the resistance mediated by inactivating functions being dependent on low rates of transport during EDP-I, means by which these rates can be increased would be advantageous in counteracting the resistance mechanism. For this reason a better understanding of the mechanisms of aminoglycoside transport in bacteria has much possible practical significance.
